Leflutrozole

Leflutrozole
Clinical data
Other namesBGS-649; CGP-47645
Routes of
administration		By mouth
Identifiers
  • 4-[(4-Cyanophenyl)-fluoro-(1,2,4-triazol-1-yl)methyl]benzonitrile
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H10FN5
Molar mass303.300 g·mol−1
3D model (JSmol)
  • C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)(N3C=NC=N3)F
  • InChI=1S/C17H10FN5/c18-17(23-12-21-11-22-23,15-5-1-13(9-19)2-6-15)16-7-3-14(10-20)4-8-16/h1-8,11-12H
  • Key:PZDLRBUQYWMNBR-UHFFFAOYSA-N

Leflutrozole (developmental code names BGS-649, CGP-47645) is an aromatase inhibitor which is under development by Mereo BioPharma and Novartis for the treatment of hypogonadism in men.[1][2] It was also under investigation for the treatment of endometriosis, but development for this indication was discontinued.[1] As of December 2017, leflutrozole is in phase II clinical trials for hypogonadism.[1]

See also

References

  1. ^ a b c "Leflutrozole - Mereo BioPharma". AdisInsight. Springer Nature Switzerland AG.
  2. ^ Corona G, Rastrelli G, Sparano C, Vignozzi L, Sforza A, Maggi M (August 2024). "Pharmacological management of testosterone deficiency in men current advances and future directions". Expert Review of Clinical Pharmacology. 17 (8): 665–681. doi:10.1080/17512433.2024.2366505. PMID 38853775.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.